Vassal G - Search Results

1

Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.

Delbaldo C, Chatelut E, Ré M, Deroussent A, Séronie-Vivien S, Jambu A, Berthaud P, Le Cesne A, Blay JY, Vassal G. Delbaldo C, et al. Among authors: vassal g. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6073-8. doi: 10.1158/1078-0432.CCR-05-2596. Clin Cancer Res. 2006. PMID: 17062683

2

Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?

Vassal G, Deroussent A, Challine D, Hartmann O, Koscielny S, Valteau-Couanet D, Lemerle J, Gouyette A. Vassal G, et al. Blood. 1992 May 1;79(9):2475-9. Blood. 1992. PMID: 1571560 Free article.

3

Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study.

Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D, Brugières L, Kalifa C, Gouyette A, Lemerle J. Vassal G, et al. Cancer Res. 1990 Oct 1;50(19):6203-7. Cancer Res. 1990. PMID: 2400986

4

Gas chromatographic-mass spectrometric assay for busulfan in biological fluids using a deuterated internal standard.

Vassal G, Re M, Gouyette A. Vassal G, et al. J Chromatogr. 1988 Jul 15;428(2):357-61. doi: 10.1016/s0378-4347(00)83928-6. J Chromatogr. 1988. PMID: 3215938 No abstract available.

5

Chronopharmacology of high-dose busulfan in children.

Vassal G, Challine D, Koscielny S, Hartmann O, Deroussent A, Boland I, Valteau-Couanet D, Lemerle J, Lévi F, Gouyette A. Vassal G, et al. Cancer Res. 1993 Apr 1;53(7):1534-7. Cancer Res. 1993. PMID: 8453619

6

Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.

Vassal G, Koscielny S, Challine D, Valteau-Couanet D, Boland I, Deroussent A, Lemerle J, Gouyette A, Hartmann O. Vassal G, et al. Cancer Chemother Pharmacol. 1996;37(3):247-53. doi: 10.1007/BF00688324. Cancer Chemother Pharmacol. 1996. PMID: 8529285

7

Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma?

Le Cesne A, Vassal G, Farace F, Spielmann M, Le Chevalier T, Angevin E, Valteau-Couanet D, Fizazi K, Cojean I, Llombard A, Tursz T, Escudier B. Le Cesne A, et al. Among authors: vassal g. J Immunother. 1999 May;22(3):268-77. doi: 10.1097/00002371-199905000-00010. J Immunother. 1999. PMID: 10335487 Clinical Trial.

8

Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.

Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, Vernillet L, Risse ML, Boige V, Gouyette A, Vassal G. Santos A, et al. Among authors: vassal g. Clin Cancer Res. 2000 May;6(5):2012-20. Clin Cancer Res. 2000. PMID: 10815927 Clinical Trial.

9

Individual dosing of carboplatin based on drug monitoring in children receiving high-dose chemotherapy.

Rubie H, Doz F, Vassal G, Chastagner P, Gentet JC, Urien S, Bastian G, Drouard-Troalen L, Barberi-Heyob M, Catalin J, Chatelut E; Pharmacology Group of the Société Française de Pédiatrie Oncologique. Rubie H, et al. Among authors: vassal g. Eur J Cancer. 2003 Jul;39(10):1433-8. doi: 10.1016/s0959-8049(03)00314-9. Eur J Cancer. 2003. PMID: 12826047 Clinical Trial.

10

In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).

Bouligand J, Boland I, Valteau-Couanet D, Deroussent A, Kalifa C, Hartmann O, Vassal G. Bouligand J, et al. Among authors: vassal g. Bone Marrow Transplant. 2003 Nov;32(10):979-86. doi: 10.1038/sj.bmt.1704275. Bone Marrow Transplant. 2003. PMID: 14595385 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

342 results

Search Page

Filters